<DOC>
	<DOCNO>NCT01995188</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1b study evaluate safety pharmacokinetics DNIB0600A participant platinum-sensitive ovarian cancer ( PSOC ) Non-Squamous Non-small Cell Lung Cancer ( NSCLC ) . The maximum tolerate dose intravenously infused DNIB0600A combination carboplatin determine escalate dose cohort . The combination DNIB0600A carboplatin evaluate without bevacizumab [ Avastin ] three dose expansion cohort .</brief_summary>
	<brief_title>A Study Evaluate Safety Pharmacology DNIB0600A Participants With Platinum-Sensitive Ovarian Cancer Non-Squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) status 0 1 . Histologically documented epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer platinum sensitive . PSOC ( i.e. , epithelial ovarian cancer , primary peritoneal cancer , fallopian tube cancer ) document radiographic progression relapse within 6 18 month recent platinumbased chemotherapy . Female participant childbearing potential must use effective contraception define study protocol pregnant breastfeeding . NSCLCspecific Histological documentation incurable , locally advanced , metastatic nonsquamous NSCLC progress prior treatment Not 2 prior regimen metastatic setting , include one prior cytotoxic regimen one prior noncytotoxic regimen ( prior treatment adjuvant therapy within 6 month recurrence consider treatment regimen metastatic setting ) . For participant document epidermal growth factor receptor ( EGFR ) mutation anaplastic lymphoma kinase ( ALK ) rearrangement , one additional line noncytotoxic prior treatment permit provided therapy target agent EGFR mutation ALK rearrangement . For participant lung cancer , centrally confirm high expression sodiumdependent phosphate transporter ( NaPi2b ) immunohistochemistry ( IHC ) require ( i.e. , IHC 2+ 3+ ) . Antitumor therapy kind major surgery within 4 week prior Day 1 . For ovarian cancer participant , platinumbased chemotherapy within 6 month prior Day 1 . For ovarian cancer participant , platinum treatment two platinumbased chemotherapy regiment four anticancer regimen , overall , treatment ovarian cancer . Palliative radiation within 2 week prior Day 1 . Toxicity ( except alopecia anorexia ) prior therapy neuropathy grade &gt; 1 . Evidence significant disease condition could affect compliance protocol interpretation result . Known active infection ( except fungal nail infection ) . History liver disease human immunodeficiency virus ( HIV ) . Other malignancy within last 5 year , except adequately treat control carcinoma situ cervix skin cancer primary endometrial cancer stage &lt; /= 1B . Untreated active central nervous system ( CNS ) metastases . Prior treatment NaPi2b target therapy . BevacizumabSpecific Exclusion Criteria ( Participants Second Ovarian Expansion Cohort Only ) : Inadequately control hypertension history hypertensive crisis encephalopathy . History heart problem thrombosis within 6 month prior study start . History stroke within 6 month prior study enrollment . History significant vascular disease . History expectoration blood within 1 month prior study start blood clotting problem . Core biopsy minor surgical procedure within 7 day prior study start Serious nonhealing wound , active ulcer , untreated bone fracture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>